TYROSINE KINASE INHIBITOR; MISSENSE MUTATIONS; SOMATIC MUTATIONS; ADENOCARCINOMA; CHEMOTHERAPY; GEFITINIB; PLATFORMS; LANDSCAPE; THERAPY; DOMAIN
LUNG CANCER, v.113, pp.106 - 114
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.